Appropriate Antigen Concentrations and Timing of a Nasal Provocation Test

Purpose: We aimed to determine appropriate antigen concentrations and the right time to evaluate intranasal changes when performing a nasal provocation test (NPT). Also, we sought to analyze the diagnostic usefulness of individual nasal symptom and peak nasal inspiratory flow (PNIF).
Materials and methods: We divided 46 patients into allergic rhinitis (AR) group (n=19) and a non-allergic rhinitis (NAR) group (n=27). We performed intranasal challenge with 100 AU/mL of Dermatophagoides pteronyssinus (DP) and measured changes in nasal symptoms [scored using the visual analogue scale (VAS)] and PNIF%. If the patient showed significant changes, VAS and PNIF were assessed again after another 15 minutes. In patients without significant changes, we administered 1000 AU/mL and measured changes in nasal symptoms and PNIF% after 15 and 30 minutes.
Results: Fifteen minutes after the 100 AU/mL challenge, the AR group showed more significant VAS changes in all nasal symptoms, total nasal symptom score (TNSS), and PNIF% change than the NAR group. Among the AR group, patients who did not respond to 100 AU/mL exhibited less significant differences relative to the NAR group, even after 1000 AU/mL challenge.
Receiver operating characteristic curve analysis for VAS changes 15 minutes after 100 AU/mL challenge revealed that all nasal symptoms had area under the curve (AUC) values of ≥0.84 (p<0.001). TNSS change had an AUC value of 0.929 (p<0.001), while PNIF% change had an AUC value of 0.834.
Conclusion: We could determine the optimal concentration (100 AU/mL), timing (15 minutes after challenge), and parameters (changes in TNSS and PNIF%) when performing NPT.

Accuracy of a Novel SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Test from Standardized Self-Collected Anterior Nasal Swabs

 

Background Antigen-detecting rapid diagnostic tests (Ag-RDT) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) offer new opportunities for the quick and laboratory-independent identification of infected individuals for control of the SARS-CoV-2 pandemic. Despite the potential benefits, nasopharyngeal sample collection is frequently perceived as uncomfortable by patients and requires trained healthcare personnel with protective equipment. Therefore, anterior nasal self-sampling is increasingly recognized as a valuable alternative.
Methods We performed a prospective, single-center, point of care validation of an Ag-RDT using a polypropylene absorbent collector for standardized self-collected anterior nasal swabs. Real-time polymerase chain reaction (RT-PCR) from combined oropharyngeal/nasopharyngeal swabs served as a comparator. Primary endpoint was sensitivity of the standardized Ag-RDT in symptomatic patients with medium or high viral concentration (≥1 million RNA copies on RT-PCR for SARS-CoV-2).
 Results Between 12 February and 22 March 2021, 388 participants were enrolled. After exclusion of 9 patients for which no PCR result could be obtained, the novel Ag-RDT was evaluated based on 379 participants, of whom 273 were symptomatic and 106 asymptomatic.
In 61 samples from symptomatic patients with medium or high viral load (≥1 million RNA copies), the sensitivity of the standardized Ag-RDT was 96.7% (59/61; 95% confidence interval (CI): 88.7-99.6%) for the primary endpoint. In total, 62 positive Ag-RDT results were detected out of 70 RT-PCR positive individuals, yielding an overall sensitivity of 88.6% (95% CI: 78.7-94.9%). Specificity was 99.7% (95% CI: 98.2-100%) in 309 RT-PCR negative individuals.
 Conclusions Here, we present a validation of a Roche Antigen Nasal Test Ag-RDT with a standardized sampling process for anterior nasal self-collection, which meets World Health Organisation (WHO) criteria of ≥80% sensitivity and ≥97% specificity. Although less sensitive than RT-PCR, this assay could be beneficial due to its rapid results, ease of use, and suitability for standardized self-testing.

Custom development of ELISAs for other species or antibody isotypes not listed in the catalog. Custom testing of samples for IgG/IgM/IgA or total (IgG+IgM+IgA).

000-CUS Alpha Diagnostics Custom Ask for price

Alpha-bungarotoxin, CF405s

00002 Cusabio 500uG 494 EUR

Alpha-bungarotoxin, CF405s

00002-100ug Biotium 100uG 161 EUR

Alpha-bungarotoxin, CF680r

9-00003 Biotium
  • 494.00 EUR
  • 161.00 EUR
  • 500uG
  • 100uG

Alpha-bungarotoxin, CF680r

9-00003 Biotium
  • 494.00 EUR
  • 161.00 EUR
  • 500uG
  • 100uG

Alpha-bungarotoxin, CF640r

9-00004 Biotium
  • 494.00 EUR
  • 161.00 EUR
  • 500uG
  • 100uG

Alpha-bungarotoxin, CF640r

9-00004 Biotium
  • 494.00 EUR
  • 161.00 EUR
  • 500uG
  • 100uG

Alpha-bungarotoxin, CF488a

9-00005 Biotium
  • 494.00 EUR
  • 161.00 EUR
  • 500uG
  • 100uG

Alpha-bungarotoxin CF488a

9-00005 Biotium
  • 494.00 EUR
  • 161.00 EUR
  • 500uG
  • 100uG

Alpha-bungarotoxin, CF568

9-00006 Biotium
  • 494.00 EUR
  • 161.00 EUR
  • 500uG
  • 100uG

Alpha-bungarotoxin, CF568

9-00006 Biotium
  • 494.00 EUR
  • 161.00 EUR
  • 500uG
  • 100uG

Alpha-bungarotoxin, CF594

9-00007 Biotium
  • 494.00 EUR
  • 161.00 EUR
  • 500uG
  • 100uG

Alpha-bungarotoxin CF594

9-00007 Biotium
  • 494.00 EUR
  • 161.00 EUR
  • 500uG
  • 100uG

Alpha-bungarotoxin, CF633

9-00009 Biotium
  • 494.00 EUR
  • 161.00 EUR
  • 500uG
  • 100uG

Alpha-bungarotoxin, CF633

9-00009 Biotium
  • 494.00 EUR
  • 161.00 EUR
  • 500uG
  • 100uG

Alpha-bungarotoxin

00010-1 Biotium 1MG 168 EUR

Fluorescein-Alpha-bungarotoxin

00011 Biotium 500uG 367 EUR

Tetramethylrhodamine-Alpha-bungarotoxin

00012 Biotium 500uG 383 EUR

Fluorescein-alpha-bungarotoxin: (10x50ug)

00013 Biotium 10ST 417 EUR

Tetramethylrhodamine-alpha-bungarotoxin: (10x50ug)

00014 Biotium 10ST 466 EUR

Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (500ug)

00015 Biotium 500uG 466 EUR

Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (10x50ug)

00016 Biotium 10ST 523 EUR

Biotin-xx-a-bungarotoxin

00017 Biotium 500uG 433 EUR

Alpha-Bungarotoxin, CF555 conjugate

9-00018 Biotium
  • 494.00 EUR
  • 161.00 EUR
  • 500uG
  • 100ug

Alpha-Bungarotoxin, CF555 conjugate

9-00018 Biotium
  • 494.00 EUR
  • 161.00 EUR
  • 500uG
  • 100ug

Biotin-cAMP, diisopropylethylammonium salt:

00020 Biotium 1MG 314 EUR

Biotin-cAMP, diisopropylethylammonium salt: (20x50ug)

00020-1 Biotium 20ST 418 EUR

Biotin-cGMP, diisopropylethylammonium salt:

00021 Biotium 1MG 344 EUR

Biotin-cGMP, diisopropylethylammonium salt: (20x50ug)

00021-1 Biotium 20ST 448 EUR

Cyanine 644-cAMP:

00022 Biotium 1MG 491 EUR

Cyanine 644-cAMP: (20x50ug)

00022-1 Biotium 20ST 625 EUR

Fluorescein Methotrexate, triammonium salt:

00023 Biotium 1MG 281 EUR

Staurosporine

00025 Biotium 100uG 139 EUR

Alpha-bungarotoxin, CF543

00026 Biotium 500uG 494 EUR

Rhodamine phalloidin 300u

00027 Biotium 300 345 EUR

Leave a Comment

Your email address will not be published.